Kyto Technology and Life Science, Inc. Logo

Kyto Technology and Life Science, Inc.

KBPH

(2.8)
Stock Price

1,00 USD

16.58% ROA

0% ROE

4.87x PER

Market Cap.

13.287.600,00 USD

0% DER

0% Yield

0% NPM

Kyto Technology and Life Science, Inc. Stock Analysis

Kyto Technology and Life Science, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kyto Technology and Life Science, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (52.39%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

4 PBV

The stock's PBV ratio (2.55x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

5 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

6 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

7 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Kyto Technology and Life Science, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kyto Technology and Life Science, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

Kyto Technology and Life Science, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kyto Technology and Life Science, Inc. Revenue
Year Revenue Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 9.000 100%
2019 14.150 36.4%
2020 0 0%
2021 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kyto Technology and Life Science, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2003 25.297
2004 44.614 43.3%
2005 41.590 -7.27%
2006 80.000 48.01%
2007 120.000 33.33%
2008 220.000 45.45%
2009 150.000 -46.67%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kyto Technology and Life Science, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 4.070.000 100%
2007 370.000 -1000%
2008 160.000 -131.25%
2009 150.000 -6.67%
2010 350.000 57.14%
2011 120.000 -191.67%
2012 60.000 -100%
2013 0 0%
2014 0 0%
2015 90.000 100%
2016 90.000 0%
2017 90.000 0%
2018 239.082 62.36%
2019 726.503 67.09%
2020 225.378 -222.35%
2021 392.964 42.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kyto Technology and Life Science, Inc. EBITDA
Year EBITDA Growth
2003 -33.602
2004 -1.962.861 98.29%
2005 -3.534.185 44.46%
2006 -4.149.759 14.83%
2007 -350.000 -1085.65%
2008 -608.287 42.46%
2009 -558.097 -8.99%
2010 -397.486 -40.41%
2011 -121.423 -227.36%
2012 -231.863 47.63%
2013 -80.801 -186.96%
2014 -101.182 20.14%
2015 -90.000 -12.42%
2016 -90.000 0%
2017 -90.000 0%
2018 -230.082 60.88%
2019 -712.353 67.7%
2020 -1.739.372 59.05%
2021 -4.254.312 59.12%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kyto Technology and Life Science, Inc. Gross Profit
Year Gross Profit Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 9 100%
2019 14 35.71%
2020 0 0%
2021 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kyto Technology and Life Science, Inc. Net Profit
Year Net Profit Growth
2003 -34.846
2004 -1.963.666 98.23%
2005 -3.534.787 44.45%
2006 -4.150.000 14.82%
2007 -350.000 -1085.71%
2008 -640.000 45.31%
2009 -590.000 -8.47%
2010 -520.000 -13.46%
2011 -190.000 -173.68%
2012 -250.000 24%
2013 0 0%
2014 0 0%
2015 -90.000 100%
2016 -90.000 0%
2017 -90.000 0%
2018 -230.107 60.89%
2019 -773.399 70.25%
2020 1.397.596 155.34%
2021 4.048.056 65.47%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kyto Technology and Life Science, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 -2 100%
2005 -3 0%
2006 -3 33.33%
2007 0 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kyto Technology and Life Science, Inc. Free Cashflow
Year Free Cashflow Growth
2003 38.856
2004 -162.786 123.87%
2005 -43.235 -276.51%
2006 -169.531 74.5%
2007 -78.306 -116.5%
2008 -589.161 86.71%
2009 -525.292 -12.16%
2010 -246.432 -113.16%
2011 -92.996 -164.99%
2012 -13.160 -606.66%
2013 -10.314 -27.59%
2014 -32.581 68.34%
2015 -26.810 -21.53%
2016 -32.407 17.27%
2017 -31.319 -3.47%
2018 -205.225 84.74%
2019 -699.882 70.68%
2020 -2.470.600 71.67%
2021 -1.448.901 -70.52%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kyto Technology and Life Science, Inc. Operating Cashflow
Year Operating Cashflow Growth
2003 38.856
2004 -162.786 123.87%
2005 -43.235 -276.51%
2006 -169.531 74.5%
2007 -78.306 -116.5%
2008 -589.161 86.71%
2009 -525.292 -12.16%
2010 -246.432 -113.16%
2011 -92.996 -164.99%
2012 -13.160 -606.66%
2013 -10.314 -27.59%
2014 -32.581 68.34%
2015 -26.810 -21.53%
2016 -32.407 17.27%
2017 -31.319 -3.47%
2018 -205.225 84.74%
2019 -699.882 70.68%
2020 -2.470.600 71.67%
2021 -1.448.901 -70.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kyto Technology and Life Science, Inc. Capital Expenditure
Year Capital Expenditure Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kyto Technology and Life Science, Inc. Equity
Year Equity Growth
2003 -559.629
2004 -274.554 -103.83%
2005 -231.227 -18.74%
2006 -425.005 45.59%
2007 -119.737 -254.95%
2008 -522.070 77.06%
2009 -686.852 23.99%
2010 -1.381.936 50.3%
2011 -1.539.075 10.21%
2012 -258.612 -495.13%
2013 -372.567 30.59%
2014 -41.822 -790.84%
2015 -132.200 68.36%
2016 -226.129 41.54%
2017 -316.956 28.66%
2018 1.563.732 120.27%
2019 2.667.611 41.38%
2020 6.993.163 61.85%
2021 12.911.623 45.84%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kyto Technology and Life Science, Inc. Assets
Year Assets Growth
2003 10.939
2004 59.981 81.76%
2005 41.334 -45.11%
2006 20.000 -106.67%
2007 50.000 60%
2008 60.000 16.67%
2009 170.000 64.71%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 30 100%
2016 0 0%
2017 7.500 100%
2018 1.592.682 99.53%
2019 2.699.755 41.01%
2020 8.429.166 67.97%
2021 13.058.298 35.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kyto Technology and Life Science, Inc. Liabilities
Year Liabilities Growth
2003 570.568
2004 334.535 -70.56%
2005 272.561 -22.74%
2006 440.000 38.05%
2007 170.000 -158.82%
2008 580.000 70.69%
2009 1.120.000 48.21%
2010 1.380.000 18.84%
2011 1.540.000 10.39%
2012 260.000 -492.31%
2013 370.000 29.73%
2014 41.820 -784.74%
2015 132.230 68.37%
2016 226.130 41.52%
2017 324.460 30.31%
2018 28.950 -1020.76%
2019 32.144 9.94%
2020 1.436.003 97.76%
2021 146.675 -879.04%

Kyto Technology and Life Science, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0.21
Price to Earning Ratio
4.87x
Price To Sales Ratio
0x
POCF Ratio
-2.76
PFCF Ratio
-5.38
Price to Book Ratio
0.97
EV to Sales
0
EV Over EBITDA
-6.81
EV to Operating CashFlow
-4.8
EV to FreeCashFlow
-4.8
Earnings Yield
0.21
FreeCashFlow Yield
-0.19
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
2.18
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0.21
Income Quality
-5.79
ROE
0.29
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.36
Free CashFlow per Share
-0.36
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.81
Return on Tangible Assets
0.17
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,21
Book Value per Share
1,03
Tangible Book Value per Share
1.03
Shareholders Equity per Share
1.03
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.83
Current Ratio
6.57
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kyto Technology and Life Science, Inc. Dividends
Year Dividends Growth

Kyto Technology and Life Science, Inc. Profile

About Kyto Technology and Life Science, Inc.

Kyto Technology and Life Science, Inc. is a venture capital firm specializing in startups and early stage companies. Its investments are either in the form of secured convertible debt paying interest and offering a discount upon conversion to preferred shares, or directly into preferred shares. The firm seeks to invest in technology and life science companies. It does not lead financing transactions. The firm makes 50% investments in the United States and the remaining in Canada and Israel. KYTO Technology and Life Science, Inc. was formerly known as Kyto BioPharma, Inc. and changed its name in April 2018. Kyto Technology and Life Science, Inc. was founded in 1999 and is based in Los Altos Hills, California with an additional office in Scotts Valley, California.

CEO
Dr. Paul M. Russo Ph.D.
Employee
1
Address
13050 La Paloma Road
Los Altos Hills, 94022

Kyto Technology and Life Science, Inc. Executives & BODs

Kyto Technology and Life Science, Inc. Executives & BODs
# Name Age
1 Mr. Christian Apfel M.D., Ph.D.
Life Science Advisor
70
2 Mr. Philip Kaiser
Specialty Advisor
70
3 Dr. Phyllis Irene Gardner
Life Science Advisor
70
4 Mr. Austin R. Erlich
Tech & Business Advisor
70
5 Mr. Mark Groper
Life Science Advisor
70
6 Dr. Daniel R. Burnett M.B.A., M.D.
Life Science Advisor
70
7 Dr. Robert S. King Ph.D.
Life Science Advisor
70
8 Dr. Paul M. Russo Ph.D.
Chief Executive Officer & Chairman
70
9 Mr. Simon P. Westbrook
Chief Financial Officer
70
10 Mr. Peter D. Staple
Director & Life Science Advisor
70

Kyto Technology and Life Science, Inc. Competitors